ASX:RGS

Regeneus (RGS) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
13,076 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RGS stock logo

About Regeneus Stock (ASX:RGS)

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

RGS Stock News Headlines

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
Russell 1000 RGS Retail (^R1RGSRET)
Closing Bell: When doves fly, markets soar
Regis Corp RGS
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
Regeneus Ltd
Regis (NYSE: RGS)
Ocugen: Still Struggling
Regis Corporation (RGS)
Regeneus Ltd (RGS.AX)
See More Headlines
Receive RGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneus and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9,000
Year Founded
N/A

Profitability

Net Income
$-1,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.02 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.24
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Karolis Rosickas
    Chief Executive Officer
  • Prof. Graham Vesey Ph.D. (Age 59)
    Chief Scientific Officer & Executive Director
    Comp: $39.28k
  • Dr. Charlotte Morgan Ph.D.
    Head of Research & Development
  • Ling Leung Hang
    Company Secretary

This page (ASX:RGS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners